Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer

NCT01393990 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01393990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01393990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
September 4, 2008
Completion date
December 14, 2013
Enrollment
89 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer